

Common Targeted Therapies							
Drug	Mechanism	Used In	Pharma/ Metabolism/ Excretion	Side Effects		Antidote/ Co- Treatment	Pharmaco- genomic Biomarkers
				Short- Term	Long- Term		
Crizotinib	Inhibitor of ALK, ROS1, and NTRK1 kinases	Lymphoma NBL Others	Liver	Nausea Vomiting Diarrhea	-	-	Mutation or fusion of ALK, ROS1, NTRK1
Rituximab	Monoclonal antibody against CD20 (B-cell lineage marker)	ALL Lymphoma	-	Infusion reactions Cytokine release syndrome Pulmonary toxicity	Reactivation of viruses	-	-
Dinutuximab (ch14.18)	Monoclonal antibody against GD2 glycolipid	NBL	-	Capillary leak syndrome Hypotension Neuropathic pain Hyper-sensitivity reactions	-	-	-
Chimeric antigen receptor (CAR) T cells	Engineered patient T cells expressing modified CD19 receptors, which kill B-lineage cells	B-ALL	-	Cytokine release syndrome (fevers, myalgias, capillary leak/hypotension, resp. failure) Encephalopathy	B cell aplasia	Tocilizumab (IL6R antagonist) for severe CRS	-

Oncologic Emergencies	
Tumor Lysis Syndrome (TLS)	
Definition	<ul style="list-style-type: none"> An oncologic emergency that is caused by massive tumor cell lysis and the release of large amounts of intracellular contents (potassium, phosphate, and uric acid) into the systemic circulation Most often occurs after the initiation of cytotoxic therapy in patients with high-grade lymphomas (particularly the Burkitt subtype) and ALL Can also occur spontaneously and with other tumor types that have a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy
Pathogenesis	<ul style="list-style-type: none"> Rapid lysis of tumor cells releases large amounts of intracellular contents (potassium, phosphate, and nucleic acids) into circulation leading to hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia. Purines are metabolized to hypoxanthine and xanthine, and then to uric acid via xanthine oxidase. Uric acid is poorly soluble in water leading to crystal precipitation and deposition in the renal tubules and AKI. Allopurinol competitively inhibits xanthine oxidase, blocking the metabolism of hypoxanthine and xanthine to uric acid. Xanthine is less soluble than uric acid so allopurinol can exacerbate AKI. Cancer cells have ~4X higher Phos than normal cells. Hyperphosphatemia can lead to secondary hypocalcemia and renal calcium phosphate precipitation. Hypocalcemia may also cause cardiac arrhythmias. Elevated uric acid and phosphate worsen the severity of AKI (increases precipitation of each other)

Oncologic Emergencies continued on next page →